CanBas
Numazu
About CanBas
CanBas is a biopharmaceutical company that research and develops anti-cancer drugs. The company develops CBP501 which completes phase II clinical trials for the treatment of malignant pleural mesothelioma and non-small cell lung cancers. It also develops CBS9106, a reversible XPO-1 inhibitor for the treatment of solid tumors. CanBas is a Japan-based company that was founded in 2000.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Public
- Employees: 11 – 50
- Estimated revenue: Less than $1M
- Funding stage: IPO
- Last round: Seed (Nov 2005)
- Ticker: tyo:4575
- Website: canbas.co.jp
- Phone: +81 055-954-3666
Industries & Categories
Biopharma, Biotechnology, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/canbas-2019474 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.